Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 5, 2018- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment
- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients...
-
Jun 26, 2018
Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research New York, NY and Maidenhead, UK — 06/26/2018 The Human Vaccines Project, a nonprofit public-private...
-
Jun 22, 2018Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.
22 Jun 2018 KING OF PRUSSIA, Pa. – June 22, 2018 – An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring’s 2018 Prof. Heimburger Award...
-
Jun 15, 2018- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients - CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress
15 Jun 2018 LISBON, Portugal – 15 June 2018 – Global biotherapeutics leader CSL Behring today announced that it will participate in the 4th Congress of the European Academy of Neurology (EAN)...
-
Jun 1, 2018
$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...
-
May 31, 2018• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions • New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
31 May 2018 KING OF PRUSSIA, Pa. – 31 May 2018 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international...
-
May 23, 2018
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...
-
May 18, 2018
CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...
-
May 15, 2018
All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...
-
May 14, 2018HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance
14 May 2018 East Brunswick, N.J. – May 14, 2018 – CEO and Managing Director of CSL Limited Paul Perreault has been named “Humanitarian Man of the Year” by the Hemophilia Association of New...
-
Apr 26, 2018Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018
26 Apr 2018 KING OF PRUSSIA, Pa. – April 26, 2018 – Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing...
-
Apr 20, 2018- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM
- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms - CSL Behring is now the only company to offer a portfolio of...
-
Apr 17, 2018
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management...
-
Apr 12, 2018CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
12 Apr 2018 MONTREAL and KING OF PRUSSIA, Pa. – April 12, 2018 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has...
-
Apr 12, 2018
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...
-
Mar 29, 2018
Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for...
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Mar 20, 2018Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
20 Mar 2018 KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s...
-
Mar 17, 2018
Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
-
Mar 16, 2018First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018 KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune...
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 15, 2018First and only subcutaneous immunoglobulin approved for the treatment of CIDP, based on findings from the largest controlled clinical CIDP study
15 Mar 2018 HATTERSHEIM, Germany – 15 March 2018 – Global biotherapeutics leader CSL Behring today announced that the European Commission (EC) has granted marketing authorization for...
-
Mar 15, 2018Life Sciences Pennsylvania recognized CSL Behring’s commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
15 Mar 2018 KING OF PRUSSIA, Pa. – March 15, 2018 – Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body,...
-
Mar 13, 2018- Industry’s role in ensuring access to medicine is an imperative, not an afterthought - Patient engagement is a key driver to strengthen access
13 Mar 2018 BARCELONA, SPAIN – March 13, 2018 – In a keynote address on patients’ access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director...
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
-
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
-
Jan 4, 2018
Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
Dec 12, 2017Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...
Dec 11, 2017CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...
Dec 7, 2017CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...
-
Dec 5, 2017The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.
05 Dec 2017 Melbourne, Australia and Vancouver, Canada: CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and...
Dec 5, 2017The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...
-
Nov 23, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Nov 16, 2017
This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...
-
Nov 9, 2017Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
09 Nov 2017 KING OF PRUSSIA, Pa. — 09 November 2017 Global biotherapeutics leader CSL Behring announced that results were published in The Lancet Neurology from its PATH study (Polyneuropathy...
-
Nov 8, 2017
Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. 08 Nov 2017 New fill-and-finish facility...
-
Oct 29, 2017A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo
29 Oct 2017 KING OF PRUSSIA, Pa. — 29 October 2017 Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median...
-
Oct 24, 2017- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US - Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks
24 Oct 2017 KING OF PRUSSIA, Pa — 24 October 2017 Global biotherapeutics leader CSL Behring announced today that new data will be presented for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous...
Oct 17, 2017Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance...
-
Oct 12, 2017There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.
12 Oct 2017 KING OF PRUSSIA, Pa. — 12 October 2017 CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA)...
-
Sep 28, 2017AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A
28 Sep 2017 TOKYO — 28 September 2017 AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA® reduces the number of injections...
-
Sep 28, 2017CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.
28 Sep 2017 KING OF PRUSSIA, Pa. — 28 September 2017 The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio...
-
Sep 27, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Sep 19, 2017CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn StateCSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
19 Sep 2017 UNIVERSITY PARK, Pa. — 19 September 2017 Penn State today announced that CSL Behring a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the...
-
Sep 14, 2017Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
14 Sep 2017 EDINBURGH, UK — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that its “Join Together” campaign at the 2017 European Society for Immunodeficiencies...
-
Sep 14, 2017Privigen shown to improve functional abilities in patients with a rare neurological condition
14 Sep 2017 KING OF PRUSSIA, Pa. — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune...
-
Sep 7, 2017- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1” - RAPID and RAPID extension trial data to be featured in poster and oral presentations
07 Sep 2017 MARBURG, Germany — 07 September 2017 Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 11 September, during the...
-
Sep 6, 2017Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)
06 Sep 2017 EDINBURGH, Scotland — 06 September 2017 Global biotherapeutics leader CSL Behring today announced that as part of its participation as a platinum sponsor of the 2017 meeting of the...
-
Aug 8, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 7, 2017
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase...
-
Jul 25, 2017- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients - Comprehensive support program offered to patients
25 Jul 2017 KING OF PRUSSIA, Pa. — 25 July 2017 Global biotherapeutics leader CSL Behring today announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...
-
Jul 21, 2017FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
21 Jul 2017 KING OF PRUSSIA, Pa. — 21 July 2017 Global biotherapeutics leader CSL Behring today announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven...
-
Jul 21, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 20, 2017
Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. 20 Jul 2017 Seqirus is now...
-
Jul 19, 2017For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
19 Jul 2017 KING OF PRUSSIA, Pa. — 19 July 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s...
-
Jul 18, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 12, 2017Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life
12 Jul 2017 BERLIN — 12 July 2017 CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates...
-
Jul 12, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 11, 2017CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017 SITGES, Spain — 11 July 2017 Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken...
-
Jul 10, 2017Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
10 Jul 2017 BERLIN — 10 July 2017 CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the...
-
Jul 6, 2017New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
06 Jul 2017 MARBURG, Germany. — 06 July 2017 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...
-
Jun 23, 2017- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder - Use of rescue medication was reduced by greater than 99 percent (1) - Subcutaneous administration builds and maintains steady-state C1-INH levels
23 Jun 2017 KING OF PRUSSIA, Pa. — 23 June 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase...
-
Jun 21, 2017
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather...
-
Jun 9, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jun 1, 2017
Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical...
-
May 19, 2017Driven by its promise to save lives and protect people’s health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
19 May 2017 KING OF PRUSSIA, Pa. — 19 May 2017 CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...
-
May 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 16, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 11, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 19, 2017- AFSTYLA is the first and only single-chain recombinant factor VIII product to treat haemophilia A.
19 Apr 2017 MELBOURNE, Australia — 19 April 2017 AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA reduces the number of...
-
Apr 12, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 10, 2017CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
10 Apr 2017 MONTREAL and KING OF PRUSSIA, Pa. — 10 April 2017 CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia...
-
Apr 7, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 3, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 31, 2017CSL Behring Sponsors the First Network of its Kind on the African Continent
31 Mar 2017 LIVINGSTONE, ZAMBIA — 31 March 2017 Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...
-
Mar 29, 2017CSL Behring’s Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.
29 Mar 2017 KING OF PRUSSIA, Pa — 29 March 2017 Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...
-
Mar 24, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 24, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...
-
Mar 21, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 1, 2017PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy
01 Mar 2017 KING OF PRUSSIA, Pa — 01 March 2017 Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...
-
Feb 25, 2017
Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. 25 Feb 2017 The company, which is part of global...
-
Feb 22, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Feb 20, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Feb 14, 2017FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
14 Feb 2017 KING OF PRUSSIA, Pa — 14 February 2017 Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
Feb 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 10, 2017An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 11, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 9, 2017- CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A
09 Jan 2017 MARBURG, Germany — 09 January 2017 CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A The therapy has been specifically designed for greater...
-
Jan 9, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 5, 2017
05 Jan 2017 CAMBRIDGE, MA — 05 January 2017 Momenta to receive $50 million upfront license fee and up to 4550 million in potential milestone payments from CSL Momenta to host a conference call...
-
Dec 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 21, 2016CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.
21 Dec 2016 CSL Limited (ASX:CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability...